文献速递冠心病肺血管病与心包/心肌炎血脂与心血管预防

COMPASS试验:糖尿病合并心血管疾病中抗血小板联合抗凝的获益分析

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
PubMed 文献 · Circulation · 2020-03-28

COMPASS试验预设分析比较利伐沙班2.5mg每日两次联合阿司匹林100mg每日一次与安慰剂联合阿司匹林在糖尿病和非糖尿病患者中预防主要血管事件的效果。结果显示,联合治疗在两组中相对风险降低相似,但糖尿病患者因基线风险更高,绝对获益更大,包括全因死亡率降低幅度约为非糖尿病患者的3倍。

要点

  • 利伐沙班2.5mg每日两次联合阿司匹林在糖尿病与非糖尿病患者中相对风险降低相似。
  • 糖尿病患者绝对风险降低更大,全因死亡率降低幅度约为非糖尿病患者的3倍。
  • 出血风险在两组间相似,预设净获益在糖尿病患者中尤为有利。

核心结论

  • 在稳定性动脉粥样硬化患者中,阿司匹林联合利伐沙班2.5mg每日两次在糖尿病与非糖尿病患者中均提供相似的相对获益,但糖尿病患者绝对获益更大。

研究设计与样本

  • COMPASS试验的预设分析,共纳入10 341例糖尿病患者和17 054例非糖尿病患者,比较利伐沙班(2.5mg每日两次)联合阿司匹林(100mg每日一次)与安慰剂联合阿司匹林。

主要发现

  • 主要疗效终点(心血管死亡、心肌梗死或卒中)在糖尿病组风险比0.74(P=0.002),非糖尿病组风险比0.77(P=0.005),交互作用P=0.77。
  • 全因死亡率在糖尿病组风险比0.81(P=0.05),非糖尿病组风险比0.84(P=0.09),交互作用P=0.82。
  • 3年主要疗效终点绝对风险降低在糖尿病组为2.3%,非糖尿病组为1.4%(Gail-Simon定性交互作用P<0.0001)。
  • 3年全因死亡率绝对风险降低在糖尿病组为1.9%,非糖尿病组为0.6%(交互作用P=0.02)。
  • 预设净获益在糖尿病组为2.7%,非糖尿病组为1.0%(Gail-Simon定性交互作用P=0.001)。

临床怎么用

  • 对于合并糖尿病的稳定性动脉粥样硬化患者,可考虑阿司匹林联合利伐沙班2.5mg每日两次以进一步降低主要血管事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with established coronary artery disease or peripheral artery disease often have diabetes mellitus. These patients are at high risk of future vascular events. METHODS: In a prespecified analysis of the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies), we compared the effects of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included all-cause mortality and all major vascular events (cardiovascular death, myocardial infarction, stroke, or major adverse limb events, including amputation). The primary safety end point was a modification of the International Society on Thrombosis and Haemostasis criteria for major bleeding. RESULTS: There were 10 341 patients with diabetes mellitus and 17 054 without diabetes mellitus in the overall trial. A consistent and similar relative risk reduction was seen for benefit of rivaroxaban plus aspirin (n=9152) versus placebo plus aspirin (n=9126) in patients both with (n=6922) and without (n=11 356) diabetes mellitus for the primary efficacy end point (hazard ratio, 0.74, P=0.002; and hazard ratio, 0.77, P=0.005, respectively, Pinteraction=0.77) and all-cause mortality (hazard ratio, 0.81, P=0.05; and hazard ratio, 0.84, P=0.09, respectively; Pinteraction=0.82). However, although the absolute risk reductions appeared numerically larger in patients with versus without diabetes mellitus, both subgroups derived similar benefit (2.3% versus 1.4% for the primary efficacy end point at 3 years, Gail-Simon qualitative Pinteraction<0.0001; 1.9% versus 0.6% for all-cause mortality, Pinteraction=0.02; 2.7% versus 1.7% for major vascular events, Pinteraction<0.0001). Because the bleeding hazards were similar among patients with and without diabetes mellitus, the prespecified net benefit for rivaroxaban appeared particularly favorable in the patients with diabetes mellitus (2.7% versus 1.0%; Gail-Simon qualitative Pinteraction=0.001). CONCLUSIONS: In stable atherosclerosis, the combination of aspirin plus rivaroxaban 2.5 mg twice daily provided a similar relative degree of benefit on coronary, cerebrovascular, and peripheral end points in patients with and without diabetes mellitus. Given their higher baseline risk, the absolute benefits appeared larger in those with diabetes mellitus, including a 3-fold greater reduction in all-cause mortality. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bhatt DL, Eikelboom JW, Connolly SJ, et al. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation. 2020. PMID: 32223318. doi:10.1161/CIRCULATIONAHA.120.046448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。